Mesoblast (MESO) Gains from Investment Securities (2014 - 2023)
Mesoblast (MESO) posted Gains from Investment Securities of $5.0 million for Q4 2025, up 736.97% sequentially from -$779000.0 in Q4 2024, and up 736.97% YoY from $592852.5 in Q4 2024.
Powered by 
Analysis
Mesoblast (MESO) Gains from Investment Securities (2014 - 2023) Analysis & Trends
Mesoblast has reported Gains from Investment Securities for 12 years, with the latest figure at $5.0 million in Q4 2025.
- Quarterly Gains from Investment Securities rose 736.97% year-over-year to $5.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.0 million (up 736.97% YoY) and the FY2022 annual result came in at $5.9 million, down 68.45% from the prior year.
- Gains from Investment Securities climbed to $5.0 million in Q4 2025 per MESO's latest filing, from -$779000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $5.3 million in Q2 2022 and troughed at -$5.9 million in Q4 2022.
- A 5-year average of $589833.3 and a median of $628000.0 in 2021 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 1495.71% in 2022, down 1579.77% in 2022.
- Over 5 years, Gains from Investment Securities stood at -$351000.0 in 2021, then slumped by 1579.77% to -$5.9 million in 2022, then jumped by 137.4% to $2.2 million in 2023, then slumped by 135.33% to -$779000.0 in 2024, then jumped by 736.97% to $5.0 million in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $5.0 million, -$779000.0, and $2.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -8.77 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 1.52 Mn |
| Sep 30, 2022 | -4.47 Mn |
| Jun 30, 2022 | -312,000.00 |
| Mar 31, 2022 | 672,000.00 |
| Dec 31, 2021 | -351,000.00 |
| Sep 30, 2021 | -280,000.00 |
| Jun 30, 2021 | -36.79 Mn |
| Mar 31, 2021 | 1.53 Mn |
| Dec 31, 2020 | 1.46 Mn |
| Sep 30, 2020 | 15.11 Mn |
| Mar 31, 2020 | 2.16 Mn |
| Dec 31, 2019 | -882,000.00 |
| Sep 30, 2019 | -288,000.00 |
| Jun 30, 2019 | -2.91 Mn |
| Mar 31, 2019 | -2.72 Mn |
| Dec 31, 2018 | -11,000.00 |
| Sep 30, 2018 | 622,000.00 |
| Jun 30, 2018 | 2.66 Mn |